STTK Shattuck Labs, Inc.

Nasdaq shattucklabs.com


$ 2.00 $ 0.09 (4.76 %)    

Tuesday, 11-Nov-2025 15:55:01 EST
QQQ $ 624.62 $ 0.00 (0 %)
DIA $ 480.27 $ 0.00 (0 %)
SPY $ 684.90 $ 0.00 (0 %)
TLT $ 89.71 $ 0.00 (0 %)
GLD $ 379.70 $ 0.00 (0 %)
$ 1.98
$ 1.89
$ 1.85 x 2,000
$ 2.05 x 200
-- - --
$ 0.69 - $ 2.71
121,791
na
125.29M
$ 1.53
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-06-2025 09-30-2025 10-Q
2 08-14-2025 06-30-2025 10-Q
3 05-01-2025 03-31-2025 10-Q
4 03-27-2025 12-31-2024 10-K
5 11-14-2024 09-30-2024 10-Q
6 08-01-2024 06-30-2024 10-Q
7 05-02-2024 03-31-2024 10-Q
8 02-29-2024 12-31-2023 10-K
9 11-09-2023 09-30-2023 10-Q
10 08-10-2023 06-30-2023 10-Q
11 05-09-2023 03-31-2023 10-Q
12 02-23-2023 12-31-2022 10-K
13 11-09-2022 09-30-2022 10-Q
14 08-11-2022 06-30-2022 10-Q
15 05-12-2022 03-31-2022 10-Q
16 03-15-2022 12-31-2021 10-K
17 11-09-2021 09-30-2021 10-Q
18 08-12-2021 06-30-2021 10-Q
19 05-10-2021 03-31-2021 10-Q
20 03-16-2021 12-31-2020 10-K
21 11-13-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 shattuck-labs-q3-eps-014-inline-sales-1000m-down-from-2997m-yoy-cash-balance-of-861m-expected-to-provide-cash-runway-into-2029

As of September 30, 2025, cash and cash equivalents and short-term investments were approximately $86.1 million. Shattuck's...

 shattuck-lab-files-for-resale-of-up-to-1053m-shares-of-common-stock

-SEC Filing

 wedbush-initiates-coverage-on-shattuck-labs-with-outperform-rating-announces-price-target-of-4

Wedbush analyst David Nierengarten initiates coverage on Shattuck Labs (NASDAQ:STTK) with a Outperform rating and announces ...

 shattuck-labs-ind-for-sl-325-now-in-effect-preclinical-data-shows-high-affinity-dr3-binding-and-favorable-safety-profile

– SL-325 is a potentially first-in-class DR3 antagonist antibody being developed for the treatment of Inflammatory Bowel Diseas...

 leerink-partners-maintains-outperform-on-shattuck-labs-lowers-price-target-to-2

Leerink Partners analyst Faisal Khurshid maintains Shattuck Labs (NASDAQ:STTK) with a Outperform and lowers the price target...

 needham-reiterates-hold-on-shattuck-labsto-hold

Needham analyst James Ricchiuti reiterates Shattuck Labs (NASDAQ:STTK) from Hold to Hold.

 shattuck-labs-q2-eps-024-inline

Shattuck Labs (NASDAQ:STTK) reported quarterly losses of $(0.24) per share which met the analyst consensus estimate. This is a ...

 shattuck-labs-secures-up-to-103m-in-private-placement-financing-through-securities-purchase-agreement

– Aggregate net proceeds expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Dise...

 shattuck-labs-management-to-participate-in-dr3tl1a-focused-panel-discussion-and-in-one-on-one-meetings-at-leerink-partners-therapeutics-forum-ii-and-metabolism

Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a biotechnology company pioneering the development of novel therapeutics targetin...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION